Rapport Therapeutics, Inc. Common Stock

Day range

$25.54 – $27.95

Open

$26.02

Prev close

$25.93

Volume

634.41K

Market cap

$1.24B

Shares out

47.98M

P/E

—

P/S

62.20

P/B

2.94

P/FCF

—

ROE

-32.4%

ROA

-29.9%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationOct 20, 2026

  The Company will make available a copy of the presentation from the webcast on the "Investors" page of the Company's website at www.rapportrx.com and is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

• Annual meeting resultsJun 10, 2026

  On June 10, 2026, Rapport Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders. The Company's stockholders voted on the following matters: (i) to elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II directors of the Company...and (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Clinical trial resultsApr 21, 2026

  On April 21, 2026, the Company announced results from the 8-week follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures ('FOS'). In the first four weeks of follow-up (weeks 9-12), RAP-219 showed even greater reductions in LEs and clinical seizures than were observed during the 8-week treatment period. Patients experienced an 80% median reduction in LEs and 90% median reduction in clinical seizures compared to baseline in weeks 9-12.

• Investor presentationJan 7, 2026

  On January 7, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the 'Investors' page of the Company's website.

• Public offeringJan 7, 2026

  The Company filed the Prospectus Supplement for the purpose of registering the offer and sale of shares of its common stock having an aggregate offering price of up to $110,000,000 (the "Shares") from time to time through or to Leerink Partners LLC ("Leerink") and Cantor Fitzgerald & Co. (together with Leerink, the "Sales Agents") acting as sales agents, pursuant to the existing Sales Agreement, dated July 1, 2025.

• SNTGSentage Holdings Inc. Class A Ordinary Shares+1.80%

Days to cover

4.8

Short interest

3.19M

Avg volume

660.1K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
  positiveGlobeNewswire Inc.· Oct 20, 2026
• The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
  negativeZacks Investment Research· Sep 23, 2026
• Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
  positiveGlobeNewswire Inc.· Apr 1, 2026
• Rapport Announces Pricing of Public Offering of Common Stock
  neutralBenzinga· Sep 9, 2025
• Analysts Can't Get Enough of These Little-Known Biopharma Stocks
  positiveInvesting.com· Jun 12, 2025